Ginkgo Bioworks Holdings Inc vs Flagstar Bank NA — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.01 (market cap $590.53M), while Flagstar Bank NA trades at $15.12 (market cap $6.24B). The key difference: Flagstar Bank NA is far larger — about 10.6× Ginkgo Bioworks Holdings Inc's market cap, and Flagstar Bank NA pays a 0.27% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | FLG | |
|---|---|---|
Market Cap | $590.53M | $6.24B |
Sector | Health | Financials |
52-Week High | $16.14 | $15.28 |
52-Week Low | $5.48 | $10.72 |
Enterprise Value | $627.78M | — |
Dividend Yield | — | 0.27% |
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Flagstar Bank (FLG) trades at $14.88, down 1.39% today, with a bullish technical outlook supported by moving averages. The stock shows improving fundamentals with two consecutive quarterly EPS beats and a positive Q1 2026 net income of $0.04 per share. Recent news highlights management's focus on technology transformation and balance sheet stabilization, while the P/B ratio of 0.82 indicates potential undervaluation relative to book value.
The outlook is cautiously optimistic with a consensus price target of $17.05 offering 14.6% upside. Risks include negative net income margins and high interest expenses, but analyst sentiment is positive with no sell ratings. The upcoming Q2 2026 earnings report on July 24, 2026, will be critical for confirming the turnaround trajectory.
Trailing returns across standard periods
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →